Skeletal muscles and bones form a joined functional unit sharing a complex mechanical, biochemical and hormonal crosstalk. A number of factors, including sex hormones, physiologically regulate the musculoskeletal system. Striking gender differences in muscle and bone mass, and function are mainly caused by distinct actions exerted by oestrogens and androgens. However, relaxin and relaxin-related peptides, such as insulin-like peptide 3 (INSL3), might contribute to these sex-associated differences in physiological and pathological conditions (such as osteoporosis and sarcopenia). Relaxin is a 'pregnancy' hormone, but it is also produced from the prostate gland, and has recently attracted attention as a potential drug for cardiovascular disorders and fibrosis. In contrast, INSL3 is a male-specific hormone produced by the Leydig cells of the testis with a fundamental role in testicular descent during fetal life. Recent evidence suggests that both hormones have interesting roles in the musculoskeletal system. Relaxin and INSL3, by finely tuning bone formation and resorption, are involved in bone remodelling processes, and relaxin contributes to the healing of injured ligaments and promotes skeletal muscle regeneration. Here, we review the most recent findings on the effects of relaxin and INSL3 on skeletal muscle and the cell components of bone. In the light of the experimental evidence available and animal models, their clinical implications are also discussed.
Introduction
There is increasing evidence showing that skeletal muscles and bones have a reciprocal effect on each other through a multilevel and bi-directional dialogue. Indeed, skeletal muscles and bones form a joined functional unit sharing a complex mechanical, biochemical and hormonal crosstalk. This tight relationship exists during embryonic development, when these tissues are formed from somites originating from the paraxial mesoderm (Pourquié, 2001) . During the development of the skeleton, mechanical load exerted by the contraction of the growing muscle contributes to skeletal definition, whilst skeletal adaptations regulate muscle forces (Land and Schoenau, 2008) . Beyond a mere mechanical interaction, both muscle and bone exhibit vigorous secretory/endocrine activity. Muscle-secreted factors, namely 'myokines', have been demonstrated to influence angiogenesis (such as IL-8) (Pedersen et al., 2007) , adipocyte metabolism (such as irisin) (Seale et al., 2008) and bone mineral content (such as IL-15) (Dallas et al., 2013) . However, osteocalcin, a protein produced by the late osteoblast before embedding into osteoid and by embedded osteocytes, is thought to have a direct effect on muscle strength, and its serum levels increase after physical exercise (Fernandez-Real et al., 2009; Levinger et al., 2014) . Moreover, prostaglandin E 2 and Wnt3a, two factors produced by osteocytes in response to shear stress, have been shown to support myogenesis and muscle function (Mo et al., 2012; Huang et al., 2014) . Therefore, the musculoskeletal system is unquestionably much more complex than just bone and muscles separately, and they represent a joined functional unit working together in health and disease (Brotto and Bonewald, 2015) .
Together with a mutual communication at the biochemical and molecular level, the musculoskeletal system is controlled at the central level, mainly by hormones. A typical example of this is somatotropin, which modulates the function of the muscle-bone unit through the activation of osteoblasts (the bone forming cells), stimulation of protein synthesis in muscle cells and increasing muscle mass (Forwood et al., 2001) . Furthermore, somatotropin acts indirectly on this system through inducing the liver to produce insulin-growth factor 1 which, together with sex hormones, induces the growth of bone and muscle mass during puberty (Barbieri et al., 2003; Hameed et al., 2003) .
Striking gender differences in muscle and bone mass and function are mainly caused by the distinct actions exerted by oestrogens and androgens. Sex hormones physiologically control many aspects of the musculoskeletal unit, and their deficiencies (as observed in menopause and male hypogonadism) are major causes of common pathological conditions, such as osteoporosis and sarcopenia.
However, relaxin, produced in humans by the RLN2 gene (Hudson et al., 1984) , and insulin-like peptide 3 (INSL3) have recently been shown to contribute to such sex-differences in physiological and pathological conditions as they exert interesting roles in the musculoskeletal system in addition to their well-known effects in female and male reproduction (Foresta et al., 2004a; Conrad and Baker, 2013) . Relaxin is a 'pregnancy' hormone, but it is also produced in the prostate gland, and has recently attracted particular attention as a potential drug for cardiovascular disorders and fibrosis. Therefore, understanding its effects on the musculoskeletal system has become especially important in drug development. In contrast, INSL3 is a male-specific hormone produced by the Leydig cells of the testis with a fundamental role in testicular descent in the foetus. However, high levels are produced throughout life, and its plasma levels are reduced when the function of Leydig cells is impaired (Ferlin et al., 2013) . Recenlty, these data have led to the concept that INSL3 is a reliable and sensitive marker of Leydig cell function and that low INSL3 concentrations or activity might contribute to the signs and symptoms of male hypogonadism together with testosterone (Ferlin et al., 2013) .
Here, we review the most recent data on the effects of relaxin and INSL3 on skeletal muscle and the cell components of the bone. Taken together, these studies show that relaxin and INSL3 are involved in bone remodelling processes by finely tuning bone formation and resorption, and relaxin contributes to both the healing of injured ligaments and promotion of skeletal muscle regeneration. Alexander et al., 2015a,b,c) .
Effects of relaxin on bone
mineralization. The OB is one of the cells derived from the differentiation of mesenchymal stem cells, together with adipocytes and chondrocytes. The differentiation of mesenchymal stem cells into OBs is typically induced by different substances in the interstice, from metabolites, to hormones and growth factors, but a common stimulus is the upregulation of runt-related transcription factor 2 (RUNX-2), the key osteogenic transcription factor (Hsu and Kiel, 2012) . Downstream effects of RUNX-2 activation are an increased synthesis and release of bone proteins in the extracellular space (type 1α collagen, osteonectin, osteopontin, osteocalcin, etc.) and the increased expression and activity of alkaline phosphatase (ALP) whose role in mineralization is well known (Whyte, 1994) . OB also influences OC activity through the release of receptor activator of NF-κB ligand (RANKL), a typical pro-osteoclastogenetic factor, and osteoprotegerin (OPG), a decoy receptor of RANKL with bone spearing properties (Findlay and Atkins, 2011) . Considering that the main organic constituent of bone is type I collagen (Karim and Bouxsein, 2015) , it is not surprising that a major regulator of collagen catabolism such as relaxin plays an important role in bone metabolism. However, the notion that relaxin might exert a direct effect on OB is fairly recent. In 2011, in a study aimed to evaluate the effects of oestrogens and relaxin on the RANKL-OPG system, Ho et al. observed that the administration of purified porcine relaxin in a mouse model of adjuvant-induced arthritis, synergistically enhanced the stimulant effect on the OPG serum levels exerted by oestrogens, with a resulting reduction in the RANKL/OPG ratio (Ho et al., 2011) . These authors also identified the presence of relaxin receptor RXFP1 mRNA transcripts in UMR 106-01 murine osteoblast cell line and showed that its expression was up-regulated by oestrogen stimulation (Ho et al., 2011) . Moreover, treatment of primary rat OB cultures with oestrogen and purified porcine relaxin increased the release of OPG in culture supernatant more than that induced by oestrogen alone, and also significantly reduced the RANKL/OPG ratio in line with the observed effect in vivo (Ho et al., 2011) . In addition to modifying the interstitial composition towards a reduction in osteoclastogenic stimulus, more recent data from Duarte et al. (2014) also revealed a direct effect of relaxin on the gene expression pattern of OB. In fact, stimulation of the mouse calvarial OB cell line MC3T3-E1 with recombinant human relaxin 1 increased the phosphorylation of ERK1/2 and enhanced the downstream expression of RUNX-2 and ALP, whilst down-regulating the expression of both OPG and RANKL. As a result, prolonged relaxin stimulation induced both an increase in ALP activity and an increased response in the in vitro mineralization assay, with a parallel reduction in collagen deposition and increased metalloproteinase (MMP) activity. By the use of siRNA technology, the authors found that the reported effects were mainly mediated by the RXFP2 receptor, a somewhat surprising result because this is considered to be the receptor for INSL3 (Duarte et al., 2014) . In this regard, it should be noted that while the pharmacological doses of human recombinant relaxin used in these studies can exert some effects on RXFP2 receptors in vitro, this hormone is thought to have negligible effects in vivo because mouse and rat relaxin have been demonstrated to have no effect on the RXFP2 receptor ( In addition, a direct effect of relaxin on the RXFP2 receptor is even more unlikely given the low doses of circulating relaxin, especially in males (Goh et al., 2013) . More consistent observations have shown that the effect of relaxin on OB seems to be even more extensive than the direct activation of extracellular bone matrix-deposition machinery. Moon et al. (2014) showed that recombinant human relaxin increases bone-morphogenetic protein-2 (BMP-2)-mediated recruitment of mesenchymal stem cells and differentiation into osteoblasts in the mouse embryonic cell line C3H/10T1/2. In particular, relaxin was found to potentiate the downstream activation of the MAPK-dependent canonical and noncanonical BMP-2 signalling pathway, as demonstrated by the increased phosphorylation of both Smad and TAK1 after stimulation with relaxin and BMP-2 compared to stimulation with BMP-2 alone (Moon et al., 2014) . Accordingly, relaxin was able to enhance the BMP-2-increased RUNX-2 expression and transcriptional activity, which is essential for the differentiation of mesenchymal stem cells into preosteoblasts (Lee et al., 2002) . Ablation of relaxin signalling by RXFP1 receptor siRNA severely blunted these effects, highlighting the specific involvement of this receptor. Finally, recombinant human relaxin stimulated ectopic bone formation in synergy with BMP-2 in an experimental mouse model where ectopic mineralization nuclei were induced by subcutaneous injection of type I collagen and recombinant BMP-2 (Moon et al., 2014) .
Osteoclasts
Osteoclasts (OCs) are giant, multinucleated cells that derive from the differentiation of haematopoietic mononuclear precursors. In specific microenvironments, the differentiation of OC myeloid precursors into mature OCs is strictly controlled by factors produced by OB. In OC progenitors, the binding of RANKL to RANK, its receptor, stimulates their differentiation and activity. In contrast, OPG acts as a non-signalling decoy receptor, and by binding to RANKL, it prevents the activation of RANK resulting in decreased OC recruitment. Osteoclastogenesis also requires the presence of macrophage colonystimulating factor (M-CSF), which is released by OB as well and acts on OC through its receptor, colony-stimulating factor 1 receptor (CSFR). The RANK/RANKL/OPG and M-CSF/CSFR regulatory axes couple OB and OC activity, thereby controlling the balance between bone formation and resorption (Salamanna et al., 2015) .
Initial suggestions that relaxin could be involved in bone resorption mechanism came from Kristiansson et al. in 2005 Kristiansson et al. in (2005 , who reported that primary human peripheral blood mononuclear cells respond to human relaxin at physiological levels by increasing the secretion of TNF and IL-1, two cytokines highly correlated with OC-mediated bone resorption (Thomas et al., 1999) . Similarly, Figuereido et al. (2009) , aiming to assess whether relaxin could influence monocyte activation status, showed that recombinant human relaxin induced a time-and substrate-dependent homotypic cell-cell clustering of the human monocyte cell line THP-1. This effect relied on the suppression of macrophage migration through an adenylate cyclase-independent, NO synthase-dependent mechanism as confirmed by the use of the RAW264.7 and RAW264.7 γNO(À) mouse monocyte cell line (Figueiredo et al., 2009 ).
However, the direct demonstration of a possible role of relaxin in OC metabolism has been addressed only recently by our group Ferlin et al., 2010) . We showed that human relaxin alone was able to stimulate osteoclastogenesis in vitro from primary human hamatopoietic progenitor cells. This effect overlapped with that of a known OC-inducing mixture of cytokines like RANKL, M-CSF and parathyroid hormone (PTH). Of note, the action of relaxin was probably mediated by the RXFP1 receptor, which appeared to be highly expressed in mature human OCs . The molecular phenotype of relaxininduced OCs was confirmed by the time-dependent expression of OC-specific genes in the primary in vitro osteoclastogenesis model, such as RANK, NF-κB, nuclear factor of activated T-cells (NFATc1), calcineurin-dependent 1, tartrate resistant acid phosphatase , CSFR, cathepsin K (CTSK), osteoclast-associated receptor and calcitonin receptor (CALCR) (Ferlin et al., 2010) . Therefore, relaxin-induced genes are implicated in the differentiation, survival and activation of OCs. Accordingly, relaxin-induced osteoclasts were able to produce resorption lacunae on dentine-coated culture slides at a comparable level to those OCs obtained under standard differentiating conditions employing M-CSF, RANKL and PTH (Ferlin et al., 2010) . Furthermore, relaxin induced the expression of its specific receptor RXFP1 in OCs. Interestingly, we found that relaxin was not produced by OCs. This finding, together with an absence in the expression of relaxin in human OBs (Ferlin et al., 2008a) , suggests that this hormone might act on OCs as a classic endocrine factor and not as an autocrine/paracrine substance.
Taken together, as summarized in Figure 1 , these data suggest that relaxin modulates both OB and OC activity in cell lines, animal models and humans, with an overall activation of both cell populations. Stimulation of OCs by relaxin induces bone resorption, and stimulation of OBs induces mineralization. At the same time, because relaxin also modulates the release of osteoclastogenic factors by OB, these cells show a pivotal role switching the balance of downstream relaxin action towards either a bone forming/spearing or bone remodelling process.
Many other aspects should be analysed further. In particular, the possibility that the crosstalk within the bone is actually shared by a third cellular participant, the Ocy, should be considered. Ocys are differentiated OB that do not directly participate in bone mineralization but, by being embedded in the growing matrix, instead have a regulatory function on the other bone cell populations. The Ocy represents more than 95% of bone cells in the adult skeleton, with this percentage increasing with age and bone size (Dallas et al., 2013) . The changes in gene expression that characterize the transition of OB towards an Ocy phenotype include the down-regulation of ALP and the expression of the glycoprotein sclerostin (Dallas et al., 2013) . More than a cell marker, sclerostin is an important negative regulator of bone mass through the inhibition of bone formation by OB (reviewed in Compton and Lee, 2014) . Although Ocy have emerged as key regulators of bone remodelling, the influence of relaxin on these cells has not yet been investigated. This is particularly intriguing, as we recently demonstrated that the function of these cells is regulated by androgens (Di Nisio et al., 2015) and, therefore, is probably important as a mediator of the gender differences in bone phenotype between males and females.
Effects of INSL3 on bone
The hypothesis of a possible role of INSL3 on bone has essential deductive origins. In fact, in adults, INSL3 is constitutively produced by the Leydig cells and released in serum under the longterm Leydig cell differentiation effect of luteinizing hormone (Foresta et al., 2004a; Sadeghian et al., 2005; Bay et al., 2006; Hannan et al., 2015) and serum levels of INSL3 have been suggested as a more sensitive marker than testosterone to identify impaired Leydig cell function (Foresta et al., 2004b; 
Figure 1
Effects of relaxin on bone cell populations. Relaxin stimulates the differentiation and maturation of osteoblasts from preosteoblasts lining bone surface. Osteoblasts are also directly activated by relaxin, thus favouring mineralization. An effect of relaxin on collagen deposition by osteoblasts is under debate. Relaxin also increases the expression and release of both receptor activator of NF-κB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG). RANKL has a pro-osteoclastogenic effect, whilst OPG has a bone sparing activity and it is upregulated by relaxin at a higher level than RANKL. In vivo, relaxin regulates osteoblast function by switching the downstream effects towards either a bone forming or bone remodelling process through the regulation of OPG/RANKL balance. Relaxin also stimulates in vitro formation and differentiation of osteoclasts from myeloid osteoclast precursors. Relaxin-induced osteoclasts have fully functional bone resorption activity. No effect of relaxin on osteocytes is known. A Ferlin et al. 2007; Ferlin et al., 2006 , Lottrup et al., 2014 . Moreover, the INSL3 receptor RXFP2 is expressed in many tissues besides the gubernaculum, including kidney, skeletal muscle, thyroid, pituitary gland, brain and bone marrow (Overbeek et al., 2001; Hsu et al., 2002; Foresta et al., 2004b; Dehghan et al., 2015) , and paracrine roles for INSL3 have been suggested in more organs than the sole reproductive tract (Hombach-Klonisch et al., 2003; Kawamura et al., 2004; Anand-Ivell et al., 2006a, b) . Taken together, this evidence suggested that reduced INSL3 activity, whether deriving from impaired testicular function or by INSL3/RXFP2 gene mutations, could cause or contribute to some symptoms and signs of hypogonadism, such as reduced bone density, currently attributed to testosterone deficiency (Ferlin et al., 2013) . Although the primary role of INSL3 during the fetal life in determining testis descent is well documented (Foresta et al., 2008) , the physiological roles of INSL3 in adulthood are much lower known. Similarly, although mutations in INSL3 and RXFP2 genes are known risk factors for cryptorchidism from many years (Ferlin et al., 2008b) , no phenotype was evident in adulthood until recently.
BJP
In a study in 2008 (Ferlin et al., 2008a) , we firstly reported that in a group of 25 young men with the well-characterized T222P inactivating mutation in the RXFP2 gene, 16 had significantly reduced bone mineral density. This was an unexpected finding, because no other apparent cause of osteoporosis was evident in these subjects and testosterone levels were normal. We therefore suspected that INSL3 could act directly on bone metabolism. We found that both human primary OB and mouse MG63 OB cell line express RXFP2 and human INSL3 was able to increase OB proliferation through a dose-dependent and time-dependent effect on cAMP. As a confirmation, RXFP2 À/À mice showed decreased bone mass, mineralizing surface, bone formation and OC surface compared with wild-type littermates at bone histomorphometric and micro computer-assisted tomography analyses, in agreement with the human phenotype. That study suggested for the first time a role for INSL3/RXFP2 signalling in bone metabolism and linked RXFP2 gene mutations with human osteoporosis (Ferlin et al., 2008a) . Interestingly, the low bone mass phenotype in the RXFP2 À/À mice was not caused by a hyper-resorptive state but by functional alterations in the OB compartment causing little bone formation, little mineralizing surface and ultimately, a negative balance between bone formation and bone resorption. Thus, we can summarize that INSL3 exerts a bone anabolic activity through stimulation of RXFP2 in OB. As for relaxin, we did not find expression of INSL3 in bones, and thus, the effect of INSL3 seems to be endocrine rather than autocrine/paracrine. Successively, in an in vitro study performed on primary human OB cultures, we confirmed the specificity of human INSL3 action on bone forming cells as stimulant of cell proliferation and extracellular matrix-mineralization through the major involvement of MAPK signalling pathway (Ferlin et al., 2011) . Importantly, INSL3 positively modulated the osteoclastogenesis process through dose-dependent increase of M-CSF mRNA, whereas no effect on OPG expression was observed (Ferlin et al., 2008a) . Similarly to relaxin, the role of INSL3 in OB has a double face, stimulating the bone-forming activity and influencing osteoclastogenesis through the release of a modified pattern of OC stimulating factors . 
Effects of relaxin on skeletal muscle
The known role of relaxin as effector of connective tissue composition and inhibitor of collagen deposition represented the rational of a pioneer assessment of possible influence of this hormone on fibrotic degeneration and injuries of the whole muscle apparatus, from skeletal muscle fibers to ligaments. In fact, relaxin has been firstly suggested as a protective mediator from joint contractures, a clinical condition that is typically under-represented during hormonal changes of pregnancy (Ohtera et al., 1985) . This hypothesis was further addressed by the detection of RXFP1 on fibroblasts from several ligaments, such as trapezio-metacarpal joint and oblique of the thumb, mediating the tissueremodelling action of relaxin (Cooney et al., 2009; Dragoo et al., 2009; Clifton et al., 2014) . Dealing with skeletal muscle as the main focus of this review, early reports in 2005 from Li et al. (Li et al., 2005; Li et al., 2010) showed that, in murine models, direct injection of mouse relaxin in the site of muscle damage, obtained by laceration and strain, resulted in a dosedependent decrease in fibrous scar formation and enhanced muscle regeneration in the healing zone. Moreover, treated muscles displayed greater force than those sham-injected (Li et al., 2005) . This evidence suggests wider involvement of relaxin on the physiology of skeletal muscle, beyond a strict prevention of fibrosis. Major pleiotropic activity of relaxin on muscle compartment has been recently described by Mu et al. (Mu et al., 2010) . In this study, the authors investigated the mechanisms that subtend the improving effect of relaxin on muscle fibrosis and function. Firstly, by the use of both C2C12 mouse myoblast cell line and an in vitro model of human myogenesis, purified porcine relaxin showed a direct differentiating effect towards myotubes formation through the commitment of Pax-7-positive progenitor cells, also known as 'satellite cells' (Weber et al., 2012) , that showed RXFP1 expression. Importantly, the increase of myotube formation markers associated with relaxin treatment, such as typical coalescence of myoblast cells into tubular multinucleated syncytia positive to myosin-heavy chain expression, was severely blunted by the co-incubation with an inhibitor of MMPs. In agreement with this observation, both mouse and human myoblasts incubated with purified porcine relaxin showed a strong up-regulation of MMP-1, MMP-2 and MMP-9, both at transcriptional level and at protein/functional level. In general, MMP represents key factors in stem cell metabolism, being actively involved in both mobilization of cells from their niches throughout the body and homing of committed cells within the regenerating tissue (Klein et al., 2015) . Thus, this notion well correlates with improved healing of injured muscles of purified porcine relaxin-treated mice that were associated not only with higher recruitment of Pax7-positive skeletal muscle stem cells but also with increased angiogenesis and revascularization and repressed inflammatory reaction (Mu et al., 2010) . Together with an apparent direct effect on main cell population involved in muscle regeneration, an indirect effect of relaxin on the vascular component of this district is a suggestive matter of debate. Recently, Segal et al. reported that recombinant human relaxin is able to stimulate phosphoinositide 3-kinase/protein kinase B-dependent NO production and migration of human bone marrow derived endothelial progenitor cells (BMDECs, Segal et al., 2012) .
Moreover, relaxin improved vascularization and incorporation of GFP-labelled BMDECs into sprouting vessels, in mice implanted with relaxin impregnated Matrigel pellets. This effect was likely mediated by RXFP1 because in vitro NO-production and migration of isolated BMDECs from RXFP1 knockout mice was severely blunted (Segal et al., 2012) . On the other hand, the fact that an adequate blood perfusion is functional to tissue regeneration, in terms of supply of nutrients, growth factors and oxygen, is not novel (Chaabane et al., 2013) . What is somehow novel is a vasodilating effect of relaxin on skeletal muscle microcirculation. In fact, Willcox et al., in a study performed on a blood-perfused hamster cremaster muscle preparation (Willcox et al., 2013) , reported that recombinant relaxin 2 produced a transient NO-dependent and K + channel-dependent vasodilation in skeletal muscle arterioles and stimulated capillaries to initiate conducted responses. This is in agreement with the suggested signalling pathway triggered by relaxin in the context of muscle tissue through receptor tyrosine kinase/Gi protein/phosphoinositide 3-kinase/protein kinase D1/protein kinase B/NO (Plesneva et al., 2008) . Thus, despite the low amount of data available on this topic, we can summarize a quite complex scenario (Figure 3 ). Relaxin seems to act in different and concerted phases of skeletal muscle physiology: from a direct effect on the satellite stem cell population, where relaxin stimulates myogenesis and the expression of molecular phenotype competent to cell mobilization and homing, to an indirect effect on tissue perfusion through the involvement of local vascular tree, where the hormone stimulates vasodilation and BMDEC-mediated angiogenesis. All these mechanisms seem to be important to reduce muscle fibrosis and restore trophism and perfusion after injury.
Effect of INSL3 on skeletal muscle
There is a substantial lack of data regarding a possible role of INSL3 in skeletal muscle. This is somewhat surprising, considering the effect of INSL3 on bone and the reported expression of RXFP2 receptors on muscle cells (Halls et al., 2007) . Analogies with testosterone in this context allow us to speculate that INSL3 has an effect on skeletal muscle. Both hormones are produced by the Leydig cells, and their serum levels show a peculiar overlapping trend with human muscle mass across the different stages of life, achieving a maximum after puberty and progressively decreasing after the fifth decade of life (Bay and Andersson, 2011) . Indeed, sarcopenia, together with osteoporosis and other symptoms and signs, is among the clinical conditions associated with hypogonadism (Dean et al., 2015) . Furthermore, both hormones have anabolic roles in bone, and testosterone has a clear effect on muscle mass and strength. Finally, a weak binding affinity, three orders of magnitude lower than relaxin, has been documented for INSL3 towards RXFP1 receptors in in vitro models (Halls et al., 2005 (Halls et al., , 2015 . Thus, even if a specific RXFP1 receptor-mediated effect of INSL3 cannot be completely excluded, the physiological role of this interaction is expected to be negligible. In the light of these considerations, the hypothesis that INSL3 has an anabolic role in skeletal muscle is currently under experimental evaluation by our group.
Conclusion and clinical perspectives
The data reviewed here suggest intriguing roles for relaxin and INSL3 in the musculoskeletal functional unit, which have relevance in physiology, bone and muscle pathologies, ageing and drug development.
Relaxin participates in bone remodelling by stimulating both OB activity, and therefore mineralization, and OC activity, and hence bone resorption. The balance between these two processes appears to be finely tuned by the modulation, exerted by relaxin, of anti-osteoclastogenesis factors released by OB. However, relaxin also facilitates muscle healing by enhancing the recruitment of satellite cells, improving vascular perfusion, inhibiting fibrosis and probably by promoting neo-angiogenesis. INSL3 represents a key regulator of OB activity, stimulating the extracellular matrix deposition and inhibiting the M-CSF-dependent activation of OC. Given the lack of studies, the possible anabolic role of INSL3 in skeletal muscle is one of the main fields of investigation of our group.
Major clinical issues arise from the physiological roles of these two members of the relaxin-related peptide family in the musculoskeletal system. Relaxin is mainly released by the corpus luteum and the placenta, thus it is essentially engaged during growth, pregnancy and parturition in different species of mammals (Goh et al., 2013) . Therefore, on the one hand, it is unlikely that this peptide has a physiological role in the musculoskeletal system far from the gestational scenario. On the other hand, the pharmaceutical industry is actively involved in relaxin research, especially with regard to its cardiovascular and anti-fibrotic properties. The effects of relaxin on bone and muscle should be therefore considered as 'side effects' for such a drug. Alternatively, relaxin could be a new clinical candidate for therapeutic intervention in conditions such as sarcopenia, muscle healing and trauma, bone disorders and fractures. The 'anabolic' and 'catabolic' effects of relaxin on bone metabolism probably depend on dose and timing of administration, and modulating RXFP1 receptor expression by bone cells would represent a key strategy favouring either bone formation, in the case of osteopenia or osteoporosis, or bone resorption, in the case of ectopic calcification or undesired abnormal bone deposition (Duarte et al., 2014) . It should be noted that eventual treatment with relaxin should be considered with caution, because it has relatively recently emerged that relaxin signalling is involved in human cancers, in particular in mammary (Tashima et al., 1994) , prostate (Feng et al., 2007; Vinall et al., 2011) and thyroid cancer (Hombach-Klonisch et al., 2006; Bialek et al., 2011) and osteosarcomas (MA et al., 2013; Huang et al., 2014; Marioni et al., 2015) . In this regard, relaxin is thought to be involved in metastatic tumour-driven osteolysis, in which there is increased osteoclast activity. Therefore, pharmacological research should also be aimed at identifying molecules modulating the relaxin signalling in osteoclasts in this context. Blocking the action of relaxin or inhibiting the relaxin receptor could theoretically represent a therapeutic approach for osteolytic bone metastasis, in which relaxin could be involved (Ferlin et al., 2010) .
By contrast, INSL3 is constitutively produced by the Leydig cells, and its secretion is proportional to the differentiation Figure 3 Effects of relaxin on skeletal muscle. Relaxin is involved in several mechanisms of skeletal muscle regeneration in animal models of laceration and strain. Relaxin stimulates migration of muscle progenitor cells, known as satellite cells, into the lesion. MMPs are key factors involved in satellite cell migration into the damaged fibres where they differentiate into mature skeletal muscle fibres. The extracellular matrix-degrading activity of MMPs also concurs to prevent fibrosis. RLX also increases perfusion through vasodilatation and prevents the inflammatory reaction by reducing leukocyte recruitment into the damaged area. Finally, an angiogenetic role of relaxin through the recruitment of the bone marrow-derived endothelial cell (BMDEC) population has also been suggested. status of this cell population. Thus, on the one hand, INSL3 levels change with Leydig cell numbers and during ageing, and on the other hand, the roles of INSL3 in extra genitourinary tissues are expected to persist during the whole of adult life (Bay and Andersson, et al., 2011) . Accordingly, the monitoring of INSL3 levels in serum is important as a diagnostic tool for disclosing pathological processes in INSL3 target tissues, as highlighted by recent epidemiological data on large cohorts of Australian men (Anand-Ivell et al., 2006a Atlantis et al., 2009 . This is of particular importance in ageing and ageing-related bone alterations, a typical degenerative process that could be identified by monitoring the levels of INSL3, which is known to decrease across the years (Bay et al., 2011) . However, INSL3 is not only a good biomarker of Leydig cell function (Ferlin et al., 2013) , but also a reduction in its plasma concentrations or activity might clearly have important clinical consequences, such as osteoporosis. Interestingly in a very recent study, serum INSL3 was measured in a cohort of healthy peripubertal girls, and the levels of the hormone were found to be increased in late puberty and highly correlated with markers of large follicle formation such as testosterone, androstendione, inhibin B and E2 (Hagen et al., 2015) . Moreover, specific staining for INSL3 was detected in antral follicles on surrounding theca cells, the population of ovary cells involved in androgen production (Ehrmann et al., 1995) . These findings are largely in agreement with previous observations viewing higher INSL3 and testosterone serum concentrations in patients with polycystic ovary syndrome compared with control women (Gambineri et al., 2007) . Thus, many aspects of INSL3 physiology in women resemble those of testosterone in males. Therefore, it seems quite strange that numerous clinical and pharmaceutical investigations of INSL3 have recently been devoted to male hypogonadism, hypotestosteronaemia and testosterone replacement therapy without considering the other functions of Leydig cells.
